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Background: Nasopharyngeal carcinoma (NPC) is a highly invasive and metastatic cancer. N,N’-dinitrosopiperazine
(DNP), a carcinogen with specificity for nasopharyngeal epithelium, facilitates NPC metastasis. However, the
underlying mechanism is not known.
Methods: Quantitative phosphoproteomics, using stable isotope labeling of amino acids in cell cultures, was
employed to identify phosphoproteins associated with NPC metastasis mediated by DNP. NPC cell line 6-10B, which
is relatively less metastatic, was used to investigate DNP-mediated metastasis. Boyden chamber invasion assay was
used to measure DNP-induced motility and invasion, and nude mice were used to verify DNP-mediated metastasis
in vivo. Several different phosphoproteins detected by proteomics analysis were verified by immunoblotting.
DNP-mediated metastasis facilitated by lysine-rich CEACAM1 co-isolated protein (LYRIC) phosphorylation at serine
568 was confirmed using mutations targeting the phosphorylation site of LYRIC. DNP-mediated metastasis through
LYRIC phosphorylation was confirmed in the NPC cell line CNE1. DNP-mediated LYRIC phosphorylation at serine
568 was also verified in metastatic tumors of BABL/c nude mice.
Results: Boyden chamber invasion assay indicated that DNP mediated cell motility and invasion of NPC cell
6-10B in vitro, and experiments with nude mice indicated that DNP increased 6-10B metastasis in vivo. In
the phosphoproteomics analysis, we detected 216 phosphorylation sites on 130 proteins; among these, 48
phosphorylation sites on 30 unique phosphopeptides were modulated by DNP by at least 1.5-fold. DNP mediated
the expression of phosphorylated GTPase, ferritin, LYRIC, and RNA polymerase, and it decreased the expression
of phosphorylated torsin-1A protein 1. Furthermore, DNP induced LYRIC phosphorylation at serine 568 to facilitate
cell motility and invasion, whereas DNP-mediated motility and invasion was decreased when serine 568 in LYRIC
was mutated. In another NPC cell line, CNE1, DNP also mediated cell motility and invasion followed by enhanced
phosphorylation of LYRIC at serine 568. Finally, phosphorylated-LYRIC expression at serine 568 was significantly
increased in metastatic tumors induced by DNP.
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Conclusion: DNP regulates multiple signaling pathways through protein phosphorylation, including the
phosphorylation of LYRIC at serine 568, and mediates NPC metastasis. These findings provide insights on the
complexity and dynamics of DNP-facilitated metastasis, and may help to gain a better understanding of the
mechanisms by clarifying NPC-induced metastasis.
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Nasopharyngeal carcinoma (NPC) is endemic in certain
regions of the world, particularly in Southeast Asia, with
an annual incidence of 30–80 per 100,000 people in
southern China [1]. NPC has invasive and metastatic
features, and approximately 90% of patients show cer-
vical lymph node metastasis at the time of initial diagno-
sis [2]. Therapeutic limitations in advanced NPC have
resulted in high rates of both local recurrence and dis-
tant metastasis [3-5]. However, the underlying mechan-
ism that favors this high metastasis is not clearly
understood.
Protein phosphorylation is an important molecular
event related to signaling pathways that control various
biological responses. Phosphorylation can affect the
function of a protein in many ways by increasing or
decreasing its activity, mediating translocation between
subcellular compartments, initiating/disrupting protein–
protein interactions, or affecting their stabilization in
signaling pathways [6]. Protein phosphorylation and de-
phosphorylation are regulated by the balanced activity
of protein kinases and phosphatases. Kinase-mediated
phosphorylation plays an important role in controlling
signaling pathways [7,8]. In carcinogenesis, carcinogens
may facilitate constitutive activation of some protein
kinases such as Rho-kinase, protein kinase C (PKC), epi-
thelial growth factor receptor, Bcr-Abl, and ErbB-2
[9-11]. The hyperactivation of some protein kinases has
been associated with tumor metastasis [12]. In NPC, the
carcinogen N,N’-Dinitrosopiperazine (DNP) has been re-
ported to activate Rho-kinase and PKC and promote
NPC metastasis [13].
In Chinese populations, the relative risk of NPC
associated with those consume salt-preserved fish on a
weekly or daily basis, compared with those who do not
consume salt-preserved fish, was generally in the range
1.4–3.2 and 1.8–7.5, respectively [14-19]. Consumption
of salted fish is an important source of nitrosamines.
Some bacteria can also induce the conversion of nitrates
into nitrites, forming important carcinogenic N-nitroso
compounds [20]. DNP is a predominant volatile nitrosa-
mine in salted fish [18,21,22]. DNP not only induces
NPC [21,23], but also facilitates NPC metastasis [13,24].
In clinical assays, NPC patients with lymph node metas-
tasis have a higher level of serum DNP than that in non-metastatic patients [13]. Experimental studies indicate
that DNP activates Rho-kinase and PKC, mediates ezrin
phosphorylation, induces motility and invasion of cells,
and promotes tumor metastasis [13]. As a carcinogen
for NPC, DNP may also induce the expression of other
phosphorylated proteins and activate multiple signaling
pathways that are involved in NPC metastasis. To clarify
DNP-mediated phosphorylation and associated signaling
pathways, and to identify novel signaling targets of DNP,
we employed a proteomics approach to comprehensively
identify DNP-regulated phosphoproteins and phospho-
sites by using high-resolution mass spectrometry (MS)
in combination with TiO2 phosphopeptide enrichment
and stable isotope labeling of amino acids in cell culture
(SILAC). Thirty phosphoproteins were found to be regu-
lated by DNP, most of which have not been previously
reported to be involved in NPC metastasis. Analysis of
this critical information helps us better understand the
complex mechanism by which DNP regulates cancer the
growth and proliferation of cancer cells. Many novel
signaling molecules in DNP-regulated signaling path-
ways have been identified here for the first time, includ-
ing lysine-rich CEACAM1 co-isolated protein (LYRIC)
phosphorylation at serine 568.
Methods
Reagents and antibodies
DNP was a kind gift from the Cancer Research Institute,
Central South University (Hunan, China), and its chem-
ical structure is shown in Figure 1A. Chemical reagents,
including Tris–HCl, sodium dodecyl sulfate (SDS), Na2S2O3,
K3Fe (CN)6, L-1-tosylamide-2-phenylethyl chloromethyl
ketone-treated trypsin, ethylene diamine tetraacetic acid
(EDTA), NH4HCO3, acrylamide, urea, thiourea, NP-40,
Triton-X100, DL-dithiothreitol (DTT), phenylmethane-
sulfonyl-fluoride (PMSF), 3-[(3-cholamidopropyl) dimethy
lammonio]-1-propanesulfonate, and pharmolyte, were
purchased from Sigma-Aldrich (St. Louis, MO). Lactate
dehydrogenase (LDH) assay reagents were purchased from
Autec Diagnostica Co (Botzing, Germany). The antibody
against Rho GTPase was purchased from Cell Signaling
Technology (Danvers, MA), and antibodies against fer-
ritin, RNA polymerase, and serine were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).
Torsin-1A protein 1 antibody was purchased from Abcam
Figure 1 Non-cytotoxic concentration of N,N’-dinitrosopiperazine (DNP) on the labeled 6-10B cells. A, Structure of DNP, an N-nitroso
compound. B, The labeled 6-10B cells were treated with 0.5, 1, 2, 4, 6, 8, 10, 20, 40, 80, or 100 μM DNP for 48 h before being subjected to MTT
cell viability assay. The inhibitory rates of DNP were calculated to the labeled 6-10B. C, After 6-10B cells were treated with 2, 4, 6, 8, 10, or 20 μM
DNP for 48 h, the media were subjected to LDH assay. OD indicates the relative optical density at 563 nm. The data indicate the LDH activity per
1 L media. Data are presented as means ± SD from 3 independent experiments, and statistically analyzed using the Student’s t- test (*, p < 0.05).
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from Biocompare. The phospho-antibody against LYRIC
serine 568 was purchased from Abcam. The secondary
antibodies, horseradish peroxidase-linked anti-mouse im-
munoglobulin G and anti-rabbit immunoglobulin G, were
purchased from Santa Cruz Biotechnology, Inc. Immuno-
blotting detection reagents, glutathione-sepharose 4B,
and the BCA protein assay kit were purchased from
Amersham Biosciences (Buckinghamshire, UK). Dimethyl
sulfoxide (DMSO) and 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-ulfophenyl)-2H-tetrazolium
(MTT) were purchased from Sigma-Aldrich. The Quik-
Change II Site-Directed Mutagenesis Kit was purchased
from Amersham Pharmacia Biotech (Piscataway, NJ).
Cell culture and SILAC labeling
Human NPC cell line 6-10B was purchased from State
Key Laboratory of Oncology in South China (Guangzhou,
China); human NPC cell line CNE1 was a kind gift from
the Cancer Research Institute, Central South University
(Hunan, China). These two cell lines have a low metastatic
ability [25]. The 6-10B cells were grown in Dulbecco’s
modified Eagle medium containing “light” (12C6) or
“heavy” (13C6) lysine supplemented with dialyzed fetal bo-
vine serum at 37°C for 2 weeks. At about 30% confluence,
the “heavy” labeled 6-10B cells were treated with 6 μΜ
DNP for 48 h after the labeled amino acids in cell popula-
tions were identified as being completely incorporated, fol-
lowing a previously established protocol [26]. The “light”
labeled 6-10B cells were treated with only DMSO. The
cells were then harvested and suspended with lysis buffer
(50 mM Tris–HCl pH 8.0, 1 mM EDTA, 2% SDS, 1 mM
DTT, 10 mM PMSF, 1 mM NaF, 1 mM Na3VO4, and
protease inhibitor cocktail). The lysate was centrifuged at
13,200 rpm at 4°C for 30 min. The supernatant fractions
were collected, and protein concentration was determined
by BCA assay (Pierce, Rockford, IL).MTT assay
To determine the non-cytotoxic concentration of DNP,
MTT assay was performed to determine cell viability
[27]. In brief, the labeled 6-10B cells were seeded in
96-well plates at a density of 3.5 × 103 cells/well and
treated with 0 to ~100 μM DNP for 48 h at 37°C. For
DNP treatment, the DNP crystals were dissolved in
DMSO, and appropriate amounts of DNP stock solution
were added to the cultured cells to achieve the indicated
concentrations. The cells were then incubated for the in-
dicated times. After the exposure period, the media were
removed, and the cells were washed with phosphate-
buffered saline (PBS). Then, the media were changed,
and cells were incubated with 100 μL MTT (5 mg/mL)
per well for 4 h. The number of viable cells per dish was
directly proportional to the production and detection of
formazan crystals, which was solubilized in isopropanol
and measured spectrophotometrically at 563 nm. The
inhibitory rates of DNP were calculated for the labeled
6-10B cells.
Lactose dehydrogenase (LDH) assay
To further confirm the non-cytotoxic concentration of
DNP to the labeled 6-10B cells, the LDH activity in cell
culture media was determined after DNP treatment.
Briefly, the cells were seeded in 6-well plates at a density
of 2 × 104 cells/well and treated with 0–10 μM DNP for
24 h at 37°C. After the exposure period, the media were
collected for measurement of LDH activity using the
LDH assay kit (Autec Diagnostica, Freiberg, Germany)
Cell motility and invasion assay
For cell invasion assay, the labeled 6-10B cells were treated
with the indicated concentrations of DNP for the indicated
times. After DNP treatment, the cells were removed by
trypsinization, and their invasiveness was tested using
Boyden chamber invasion assay in vitro [28]. Matrigel
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luted to 25 mg/50 mL with cold-filtered distilled water and
applied to 8-mm pore size polycarbonate membrane filters.
Treated cells were seeded in the upper part of Boyden
chamber (NeuroProbe, Cabin John, MD) at a density of
1.5 × 104 cells/well in 50 μL of serum-free-medium and
then incubated for 12 h at 37°C. The bottom chamber
also contained standard medium with 20% fetal bovine
serum. The cells invading to the lower surface of the
membrane were fixed with methanol and stained with
hematoxylin and eosin. Random fields were counted to
determine the number of invading cells under a light
microscope. To determine cell motility, the cells were
seeded in Boyden Chamber on membrane filters that
were not coated with Matrigel. Cellular migration was
measured as described in the motility assay [28]. Statis-
tical analysis was performed, corrected with cell viabil-
ity, to clarify the effect of DNP.
Animals
Twenty female nude BABL/c mice (approximately 5–6 weeks
old) were purchased from the Animal Center of Central
South University. They were maintained under laminar
airflow conditions in the Laboratory for Experiments,
Central South University. The studies were conducted
according to the standards established by the Guidelines
for Care and Use of Laboratory Animals of Central South
University.
Evaluation of the effect of DNP on NPC metastasis in
nude mice
The metastatic effect of DNP on labeled 6-10B cells was
determined in vivo as described previously with some
modifications [29]. In brief, 100-μL aliquots of labeled
6-10B cell suspensions (1 × 104 cells) with or without
DNP treatment were mixed with Matrigel and then
respectively injected into the tail veins of nude mice
(10 mice per group). Metastasis was assessed by observ-
ing metastasized nodes in lungs on day 30 post-injection.
The present study protocols were approved by the ethical
committees at Zhuhai Hospital of Jinan University and
Xiangya Hospital of Central South University.
Protein digestion in solution
The proteins were digested in solution as previously de-
scribed [30] with minor modifications. The “heavy” and
“light” labeled proteins were mixed at a ratio of 1:1 by
protein weight, and 2 mg of the mixed proteins was re-
duced at 37°C for 3 h in 10 mM DTT and subsequently
alkylated in the dark with 20 mM iodoacetamide at
room temperature for 1 h. The proteins were precipi-
tated in ice-cold buffer (50% acetone, 50% ethanol, 0.1%
HAc). The precipitated proteins were resuspended in
100 mM NH4HCO3, and initially digested with trypsin(1:50, w/w) at 37°C for 4 h. Further digestion was carried
out by adding trypsin (1:50, w/w) and incubating over-
night at 37°C. The digests were evaporated to about
20 μL in a SpeedVac centrifuge for phosphopeptide
enrichment.
Phosphopeptide enrichment using TiO2
Phosphopeptide enrichment was carried out following the
manufacture’s instructions provided with the Proteoex-
tract phosphopeptide enrichment TiO2 kit (Calbiochem,
Gibbstown, NJ). In brief, trypsin-digested samples (2 mg
mixed proteins) were diluted at the ratio of 1:4 with TiO2
Phosphobind Buffer containing 2,5-dihydroxybenzoic acid
to achieve a final volume of 200 μL. The diluted peptide
mixtures were mixed with TiO2 Phosphobind Resin and
then incubated for 10 min at room temperature. The TiO2
Phosphobind Resin was washed twice, once with Wash
Buffer 1 and once with Wash Buffer 2 from the kit. Finally,
the phosphopeptides were eluted twice from the TiO2
Phosphobind Resin using the Elution Buffer supplied in
the kit. The collected phosphopeptide solutions were
evaporated to dryness in a SpeedVac centrifuge and used
for liquid chromatography tandem MS (LC–MS/MS)
analysis.
Strong-cation exchange (SCX)-LC–MS/MS analysis
An xA linear ion trap/Orbitrap (LTQ-Orbitrap) hybrid
mass spectrometer (Thermo Electron, Bremen, Germany)
coupled with strong-cation exchange (SCX) and nano-
reverse-phase LC (Thermo Electron, Bremen, Germany)
was used to analyze the enriched phosphopeptides as pre-
viously described [31] with minor modifications. In brief,
the phosphopeptides were first loaded onto an SCX col-
umn (0.8 × 50 mm, Zorbax Bio-SCX Series II; Agilent
Technology) by using an autosampler with a flow rate of
10 μL/min, eluted with different concentrations (0, 5, 10,
40, 80, and 200 mM, and 1 M) of NH4Cl, and loaded onto
a C18 reverse-phase column (150 × 0.075 mm, Zorbax
300SB-C18, 3.5 μm, Agilent Technology) with a flow rate
of 300 nL/min for 150 min. The peptide mixtures were
further eluted with a 0–40% gradient of Buffer A (0.1%
formic acid, and 5% acetonitrile) to Buffer B (0.1% formic
acid and 95% acetonitrile), and mass of the peptides were
then detected using an LTQ-Orbitrap mass spectrometer.
This analysis was performed in a data-dependent mode in
which acquisitions were automatically switched between
MS and MS/MS. In each cycle, a full MS scan was carried
out in the Orbitrap, followed by 5 MS/MS scans for 5
most intense ions in the LTQ. When an ion had a neutral
loss peak at −98.00, −58.00, −49.00, −38.67, −32.67,
and −24.50 Da in MS/MS scan and was one of the 5 most
intense ions in MS/MS spectrum, the ion was further
selected for an MS/MS/MS scan. The neutral loss peaks at
98.00, 49.00, 32.67 and 24.50 Da indicate the losses of
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states, respectively, in the MS scan, while the 58.00 and
38.67 Da peaks indicate the loss of a phosphate group and
a H2O in peptides with 2 and 3 charge states, respectively,
in the MS/MS scan.
Phosphopeptide identification and quantitation, and
phosphosite validation
The mass list of the peaks was generated in the Mascot
generic format using DTASuperCharge V 1.31 (Source-
Forge) for database search, and the derived peak lists
were searched using the Mascot 2.2.04 search engine
(Matrix Science, London, UK) against real and decoy
IPI human databases (V3.56) containing 76,539 human
protein entries. The following search criteria were em-
ployed: full tryptic specificity was required, 2 missed
cleavages were allowed, and carbamidomethylation was
set as a fixed modification, whereas oxidation (M), phos-
pho (ST), and phospho (Y) were considered variable
modifications. Precursor ion mass tolerances and frag-
ment ion mass tolerances were 10 ppm and 0.5 Da,
respectively. Mass spectra of identified phosphopeptides
with peptide scores >10 were further processed and
validated with the MSQuant 1.5 software for post-
translational modification (PTM) score analysis and
quantitation, with default settings [32]. The SILAC ratio
normalization was automatically processed by MSQuant
1.5 software. The relative standard deviation (RSD) of
peptide quantitation was calculated as previously de-
scribed [31]. In brief, the RSD of peptide phosphoryl-
ation was determined by using average SD of all
quantified peptide counts of a unique phosphopeptide in
2 biological replicates, i.e., it was calculated using the
total SD/counts of the unique phosphopeptide. The SD
of unique phosphopeptide in a hit was automatically
generated by the MSQuant program. All the spectra of
these potential and decoy phosphopeptides were con-
firmed by manual interpretation of MS/MS ion spectra
using the criteria described previously [32,33]. Briefly,
5 filters for peptide identification were applied as fol-
lows: (1) the peptide score threshold was 10; (2) the
PTM score threshold was 14; (3) all phosphorylated
serine (p-Ser) and phosphorylated threonine (p-Thr)
peptides were required to show a pronounced neutral
loss of phosphoric acid from the precursor ion and/or
fragment ions, or to trigger the neutral loss-dependent
MS/MS/MS scan; (4) at least 3 consecutive b- and/or
y-ion series were required; and (5) the sum of peptide
and PTM scores was greater than 31. Other parameters
were those included in the default settings. The esti-
mated false positive rate based on the decoy database
search was 1.0%. For ambiguous phosphosites, the prob-
abilities for phosphorylation at each site were calculated
based on PTM scores as previously described [34].Phosphorylation sites with localization probabilities >0.75
were reported as class I phosphosites, and localization
probabilities between 0.75 and 0.25 were considered to be
class II sites. Phosphorylation sites with a localization
probability <0.25 were discarded.
Immunoblotting analysis
Cellular extracts were prepared as described previously
[27]. After DNP treatment, the cell samples were dis-
rupted with 0.6 mL lysis buffer. The cell lysates were
then subjected to centrifugation at 10000 × g for 10 min
at 4°C. The resultant protein concentration of each sam-
ple was determined using BCA Protein Assay (Bio-Rad
Laboratories, Inc., Hercules, CA). Forty micrograms pro-
tein from each sample was separated on 10% or 12%
polyacrylamide gel and transferred onto a nitrocellulose
membrane. The blot was subsequently incubated with
5% non-fat milk in PBS for 1 h to block non-specific
binding and incubated with Rho GTPase, ferritin, RNA
polymerase, Torsin-1A, or LYRIC antibody for 2 h, and
then with an appropriate peroxidase-conjugated second-
ary antibody for 1 h. All incubations were carried out at
37°C, and the membranes were washed with PBS after
the incubations. Finally, the membrane was washed
with PBS three times, and the signal was developed
using 4-chloro-1-naphthol/3,3-O-diaminobenzidine, and
the relative photographic density was quantitated by a
gel documentation and analysis system. β-actin was used
as an internal control to verify basal level expression and
equal protein loading. The abundance ratio to β-actin
was calculated.
Immunoprecipitation
Cellular extracts were prepared as described previously
[35]. The obtained supernatant was mixed with protein-
G beads, incubated for 2 h, and centrifuged for 2 min at
2000 rpm for pre-clearing. Then the supernatant was in-
cubated overnight with anti-serine antibody and protein-
G beads. The immunoprecipitates were collected and
washed 3 times with RIPA buffer (50 mM Tris, pH7.4,
150 mM NaCl, 1% NP-40, 0.25% sodium deoxycholate,
1 mM Na3VO4, 1 mM NaF, and protease inhibitor) and
finally subjected to immunoblotting analysis by Rho
GTPase, ferritin, RNA polymerase, torsin-1A or LYRIC
antibody.
Construction of expression vectors
A LYRIC DNP fragment was generated from human
genomic DNA using PCR. The primers used were Pri-
mer 1 (5′-TTCCCTCGACTATCCACTGCGT-3′) and
Primer 2 (5′-TTCACGTGTCTCG TCTGGCTTT-3′,
GenBank: AY974040.1), and the fragment was cloned
into the BamHI/XhoI site of the pcDNA3.1 vector
(Amersham Biosciences) to generate the pcDNA3.1-
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plasmid as the template, a pcDNA3.1-LYRIC mutant, in
which serine 568 was mutated into proline 568, was gen-
erated by the QuikChange II Site-Directed Mutagenesis
Kit with LYRIC mutant primers (Primer 3, 5′-TAGC
TGGGAACCTCCCAAAC-3′, and Primer 4, 5′-GTTTG
GGGGATTCCCAGCTA-3′). All constructs were con-
firmed by restriction enzyme mapping and DNA sequencing.
Gene transfection and stably transfected cell lines
The 6-10B cells were transfected with pcDNA3.1 (mock),
pcDNA3.1-LYRIC, pcDNA3.1-LYRIC-mutant using Lipo-
fectamine 2000 reagent (Life Technologies, Inc. Carlsbad,
CA) following the manufacturer’s protocol. Stably trans-
fected cell lines were obtained by selection for G418
resistance (400 μg/mL) as described previously [27] and
further confirmed by assessing LYRIC and phos-LYRIC
expression. To confirm whether DNP promotes metasta-
sis through LYRIC phosphorylation, 6-10B-pcDNA3.1, 6-
10B-LYRIC, and 6-10B-LYRIC-mutant cells were treated
with DNP, and their motility and invasiveness were
quantified using the in vitro Boyden chamber invasion
assay.
Bioinformatics analysis
The sub-cellular localization of these identified phospho-
proteins was searched against the UniProt database and
analyzed with the Gene Ontology (GO) database (http://
www.geneontology.org). These identified phosphopro-
teins were categorized by the PANTHER (Protein Ana-
lysis through Evolutionary Relationships) system based
on their biological process, molecular function, protein
class, and molecular pathway (http://www.pantherdb.org).
The signaling pathways of these identified phosphopro-
teins were mapped using the Pathway Studio program




The metastasized nodes in the nude mice lungs were
embedded, and 4-μm-thick tissue sections were made,
and deparaffinized in xylene, rehydrated in a graded
alcohol series, and treated with an antigen retrieval
solution (10 mM/L sodium citrate buffer, pH 6.0). The
sections were incubated with Lyric antibody (Biocom-
pare, dilution 1:100) or phosho-LYRIC antibody (Abcam,
dilution 1:50) overnight at 4°C. Subsequently, the sec-
tions were incubated with a biotinylated secondary anti-
body (Zhongshan, China), followed by incubation with
an avidin–biotin complex (Zhongshan, China) following
the manufacturer’s instructions. Finally, the tissue sections
were incubated with 3′,3′-diaminobenzidine (Sigma-
Aldrich) and with hydrogen peroxide for 2 min, andcounterstained with hematoxylin for 30 s. In negative
controls, the primary antibodies were replaced with
normal IgG.
Under light microscopy (Olympus), the distribution of
phospho-LYRIC in the nucleus and cytoplasm of the
cells was rated according to a score that determined the
scale of intensity of staining to the area of staining using
ImageMaster software. At least 10 high-power fields
were chosen randomly, and >100 cells were counted for
each section.
Results
Analysis of SILAC labeling efficiency
The 6-10B cell line was used as a model to investigate the
mechanism of DNP-mediated NPC metastasis. As a first
step in our study, we assessed the incorporation efficiency
of 2H4-L-lysine and
13C6
15N4-L-arginine in 6-10B cells,
and tested their complete incorporation in all proteins
after six cell doublings. Three peptides, VEVTEFEDIK,
GHYTEGAELVDSVLDVVR, and LRQPFFQK, were sepa-
rated by 4 Da, 10 Da, and 14 Da, corresponding to the
mass difference between the above-mentioned light and
heavy isotopes. The entire signal corresponded to the heavy
peptide, indicating that incorporation of 2H4-L-lysine or
13C6
15N4-L-arginine was complete.
Non-cytotoxic concentration of DNP on 6-10B cell
DNP is an important carcinogenic N-nitroso compound
for NPC, and its chemical structure is shown in
Figure 1A. In this study, we first determined the non-
cytotoxic concentration of DNP by treating the labeled
6-10B cells with various DNP concentrations for 48 h
and then subjecting the cells to an MTT assay. Com-
pared with the controls (0.01% DMSO), the inhibitory
rate of DNP on the labeled 6-10B cells was not signifi-
cantly altered at 0.5–8 μM DNP (Figure 1B; p < 0.05). To
confirm that 0.5–8 μM DNP was non-cytotoxic, LDH
activity in the cell culture media was evaluated after
DNP treatment. The data revealed that LDH activity was
not significantly altered by DNP treatment in the 0.5–
8 μM concentration range (Figure 1C; p < 0.05). This
non-cytotoxic concentration range was used in all subse-
quent experiments.
DNP induces the invasion and motility of 6-10B cells
The 6-10B cells exhibit lower metastasis, and were
therefore used to determine whether DNP induces NPC
cell metastasis. To determine whether DNP can induce
the invasion and motility of the labeled 6-10B, a
Matrigel-coated Boyden chamber was used to measure
cell invasion, and an uncoated Boyden chamber was used
to assess cell motility. After DNP treatment, the number
of invaded cells dramatically increased in the Matrigel-
coated Boyden chamber (Figure 2A-b) and the uncoated
Figure 2 DNP-induced NPC cell metastasis in vitro and vivo. A, To determine DNP-induced invasion and motility, a Matrigel-coated Boyden
chamber was used to measure 6-10B cell invasion, and an uncoated chamber for measuring cell motility. The cells invading to the lower surface
of Boyden chamber membrane were fixed with methanol and stained with hematoxylin and eosin. a, 6-10B treated with 0.01% DMSO-PBS in
Matrigel-coated Boyden chamber; b, 6-10B cells treated with DNP (6 μM) in Matrigel-coated Boyden chamber; Scale bar, 5 μm; c, 6-10B cells
treated with 0.01% DMSO-PBS in the uncoated chamber; d, 6-10B cells treated with DNP in the uncoated chamber. Scale bar, 10 μm. Arrows,
The invading cells. B, In concentration-course assays, 6-10B cells were treated with 2, 4, 6, and 8 μM DNP for 24 h. The motility and invasion of
the treated cells were analyzed. Random fields were counted to determine the number of invaded cells under a light microscope. a, Invasion of
6-10B cells at various concentrations; b, Motility of 6-10B cells at various concentrations. The results were statistically analyzed by one-way analysis
of variance (ANOVA) with post-hoc Dunnett’s test (*, p < 0.05). C, In animal experiments, 20 nude mice were randomly divided into 2 groups with
10 mice per group. One group was injected with DNP-treated 6-10B cells in Matrigel through the tail vein (1 × 104 cells/mouse). The other group
was injected with untreated 6-10B cells. After 60 days, metastatic tumors nodes in the lungs were observed under the microscope (*, p < 0.05).
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trols (Figure 2A-a, A-c). These results indicated that DNP
induces 6-10B cell invasion and motility. For dose–re-
sponse experiments, the cells were treated with 0, 2, 4, 6,
or 8 μM DNP for 24 h and seeded into Boyden cham-
bers, and the cells that invaded the lower chamber were
then counted. The number of invading cells significantly
increased after DNP treatment in a dose-dependent
manner (Figure 2B-a, lanes 2 to 5 vs. lane 1; p < 0.05).
The increase in cell invasion was at 421.7% with 6 μM
DNP (Figure 2B-a, lane 4). A similar effect was observed
in the motility of DNP-treated cells (Figure 2B-b, lanes
2 to 5 vs. lane 1; p < 0.05). Cell motility increased by
328.2% after treatment with 6 μM DNP (Figure 2B-b,
lane 4). Further, the induction of metastasis by DNP wasconfirmed in vivo when the 6-10B cells were injected
into the tail veins of BABL/c nude mice. Metastasis of
6-10B cells to the lung significantly increased after
DNP treatment (Figure 2C, right vs. left panel). These
results indicate that DNP can induce NPC cell motility
and invasion.
Identification of phosphorylated proteins and their sites
of modification
We employed 48-h DNP treatment for identifying DNP-
regulated serine/threonine phosphorylation of proteins
and their signaling components using a SILAC quantita-
tive proteomics approach. In 3 independent experi-
ments, more than 130 phosphopeptides were detected
after manual confirmation of the MS/MS spectra by
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SILAC quantitative proteomics. All MS/MS spectra are
available via the hyperlinks within Additional file 1:
Table S1. To assign the phosphorylation sites precisely
within a peptide, we used the PTM score to calculate
the probabilities of phosphorylation at each site as previ-
ously described [32]. We were able to localize 216 phos-
phosites with high confidence as class I phosphorylation
sites (p > 0.75). Approximately 49.6% of the phosphopep-
tides identified was found to be phosphorylated in a
single site, and other fractions were either phosphory-
lated doubly (34.4%), triply (15.3%), or at more (0.8%)
sites (Figure 3A). It is worth pointing out that many of
these identified phosphopeptides are important signaling
molecules such as protein kinases, receptors, phospha-
tases, and transcriptional regulators, including transcrip-
tion factors and repressors (Additional file 1: Table S1).
Properties of phosphorylated proteins and
phosphorylation sites
Figure 3B shows the distribution of identified class I phos-
phorylation sites, with 17 phosphotyrosine sites (2.7%),
21 phosphothreonine sites (9.58%), and 192 phosphoserine
sites (87.7%). Each phosphoprotein was searched against
the UniProt database (released on March 3, 2009) andFigure 3 Characterization of phosphopeptides, phosphosites, and ph
to identify DNP-regulated serine/threonine phosphorylation of proteins. To
PTM score was used to calculate the probabilities of phosphorylation at ea
single, double, triple, and quadruple (including higher) phosphorylation pe
DNP-regulated phosphoproteome. Phosphopeptides were categorized into
phosphorylation at each site based on PTM scores. Here, only class I phosp
C, Subcellular location of the phosphoproteome in vivo and GO analysis of
of 6-10B cells with or without DNP treatment.analyzed using GO. Figure 3C illustrates the GO analysis
for the identified phosphoproteome. The GO subcellular
location information was annotated for 131 phosphopro-
teins. Interestingly, several cytoplasmic phosphoproteins
are listed in the GO annotation (95, 72.5%) and in the
UniProt database (78, 59.5%).
Differential expression of phosphopeptides mediated
by DNP
SILAC quantitative analysis of phosphopeptides was uti-
lized to identify the DNP-mediated effects. Among the
identified 131 peptides, 30 peptides were quantified,
indicating significant differences in their expression
between the control and DNP-treated cells. Figure 4
shows the results of the quantitative analysis of Rho
GTPase protein 10 (Figure 4A) and torsin-1A protein 1
(Figure 4B) by SILAC. The data revealed 30 unique
phosphopeptides containing 48 phosphorylation sites
with 1.5-fold or higher changes in peak intensities in re-
sponse to DNP treatment. Additional file 2: Table S2
lists these phosphopeptides with change ratios, their
phosphosites and corresponding proteins, and the RSD.
The comparison of the absolute values of the log2 ratios
for these phosphopeptides by scatter plot analysis had
a strong correlation between two biological replicates,osphoproteins. The 6-10B cells with 48-h DNP treatment were used
assign the phosphorylation sites precisely within a peptide, the
ch site as described in the methods. A, Distribution of peptides with
ptides. B, Distribution of the Ser, Thr, and Tyr phosphosites in the
class I and class II phosphosites by calculating the probabilities for
hosites (high probability) were used to analyze the distribution.
DNP-regulated phosphoproteome. D, Total phosphoprotein scores
Figure 4 Examples of quantitative analysis by SILAC. SILAC quantitative analysis of phosphopeptides was used to identify DNP-mediated
effectors. Some peptides were quantified and showed fold differences between the control and DNP-treated cells. A, A representative mass
spectrum showing a peptide pair (GLRDpSHpSpSEEDEASSQTDLSQTISK from Rho GTPase) with a doubly charged ion differing by 3 Da and
exhibiting a H/L (of XIC) ratio of 0.35802; B, A representative mass spectrum a peptide pair (KFNMIPFEHRpSGGK from torsin-1A protein 1)
with triply charged ions differing by 2 Da and exhibiting a H/L (of XIC) ratio of 3.2498.
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http://www.biomedcentral.com/1471-2407/14/243with a Pearson coefficient of 0.874, indicating the repro-
ducibility of these results (Figure 5A). To determine the
quantitation error of phosphopeptides, DNP-regulated
protein expression changes were used to determine the
median H/L ratio. As shown in Figure 5B, a majority
(76.9%) of the proteins was not influenced by DNP, and
the SILAC ratio distribution was reasonable. Among the
30 different phosphopeptides, the phosphorylation of 48
phosphosites was inhibited by DNP, while the phosphor-
ylation levels of only 10 were up-regulated (Additional
file 2: Table S2). Moreover, the up-regulated peptides
were phosphorylated at serine and tyrosine residues,
but not at threonine. Serine/threonine phosphorylation
sometimes attenuates the activation of signaling mole-
cules through negative feedback [36,37]. The expression
of phosphorylated peptides/proteins is probably regu-
lated by DNP through one or more of the following
methods: (1) decreasing protein expression, (2) decreas-
ing the degree of protein phosphorylation, or (3) inducing
novel phosphorylation. Among the 30 phosphoproteins, we
identified 3 receptors, 1 signal adaptor, 5 protein kinases, 2
protein phosphatase regulatory subunits, 10 transcriptionalregulators, and other signaling molecules as being regulated
by DNP (Additional file 2: Table S2). These were the key
components in the signaling pathways mediated by DNP.
Validation of different phosphoproteins
To verify phosphorylation levels of different proteins,
the up-regulated proteins LYRIC, RNA polymerase, fer-
ritin, and Rho GTPase were detected using phospho-
serine antibody by immunoprecipitation and immuno-
blotting. Compared with the control, the phosphorylated
forms of Rho GTPase (Figure 6A), ferritin (Figure 6B),
LYRIC (Figure 6C), and RNA polymerase (Figure 6D)
increased in the 6-10B cells with DNP treatment. Simi-
larly, the decrease in the expression of phosphorylated
torsin-1A protein 1 in 6-10B cells treated with DNP was
also confirmed. DNP down-regulates the expression of
these phosphoproteins (Figure 6E). The trends of these
immunoblotting results, for all the selected proteins,
were consistent with the corresponding SILAC quantita-
tive ratios, which indicate the potential association with
cancer metastasis.
Figure 5 Estimation of the correlation between log 2 phosphopeptide ratios in 2 independent experiments and quantitation error of
SILAC ratios of DNP-regulated proteins. A, Two biological replicates were analyzed to compare absolute values of the log2 ratios for the
phosphopeptides using scatter plot analysis. The “ratio-of-ratios” correlation between log2 phosphopeptide ratios obtained from 2 independent
experiments. B, To determine the quantitation error of phosphopeptides, DNP-regulated protein expression changes were used to determine the
median H/L ratio.
Figure 6 Validation of SILAC-based quantitation by immunoprecipitation and immunoblotting. After treatment of the 6-10B cells with
DNP (6 μM), cellular proteins were extracted as described in the methods. Rho-GTPase (A), ferritin (B), LYRIC (C), RNA polymerase (D), and torsin-1A
protein 1 (E) were immunoprecipitated from the protein samples by using their corresponding antibodies, and then serine phosphorylation in the
immunoprecipitated mixture was detected by immunoblotting using phospho-antibody against serine. The relative immunoblotting ratio of the
phosphorylation level of every protein was normalized to its corresponding immunoprecipitated protein. IP, immunoprecipitation. IB, immunoblotting.
SILAC, stable isotope labeling by amino acids in cell culture.
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http://www.biomedcentral.com/1471-2407/14/243DNP-mediated invasion and motility is facilitated by
phospho-LYRIC expression
LYRIC, also known as metastasis adhesion protein
[38,39], has been shown to promote tumor cell migra-
tion and invasion [39]. To investigate whether DNP-
mediated LYRIC is involved in NPC metastasis, we first
detected phospho-LYRIC expression in NPC tissues, and
found that phospho-LYRIC Ser 568 is highly expressed
in NPC tissues, which was expressed at higher levels in
metastatic tissues than in primary site tissues (Additional
file 3: Figure S1). COOH terminal-extended (amino acid
546–582) is the predominant site of regulation of nu-
clear localization, and its modification by ubiquitin regu-
lates LYRIC nuclear localization [40]. Because our MS/
MS data indicate that DNP mediates the phosphoryl-
ation of LYRIC at serine 568, we speculate that this
phosphorylation influences NPC metastasis. To deter-
mine whether DNP-mediated LYRIC phosphorylation
participates in NPC metastasis, the cells were transfected
with pcDNA3.1-LYRIC. The cell motility and invasion
were dramatically increased after transfection (Figure 7B,
p < 0.05). When the cells were then transfected with
pcDNA3.1-LYRIC-mutant, in which the LYRIC phos-
phorylation site at serine 568 was mutated (Figure 7A,
lane 3 in upper panel), DNP-induced motility and inva-
sion were considerably decreased (Figure 7B, lanes 3 and
4; Figure 7C, lanes 3 and 4). However, DNP could effect-
ively induce cell motility (Figure 7C, lane 1 vs. 2, p < 0.05;
Figure 7C, lane 5 vs. 6, p < 0.05) and invasion (Figure 7B,
lanes 1 vs. 2, p < 0.05; Figure 7B, lanes 5 vs. 6, p < 0.05)
when the LYRIC was not mutated. LYRIC phosphorylation
at serine 568 may play an important role in DNP-
mediated NPC metastasis. To confirm whether DNP has a
similar effect on other NPC cells, the NPC cell line CNE1
was used to detect phospho-LYRIC, LYRIC, motility and
invasion after DNP treatment. The results showed that
DNP could effectively induce CNE1 motility (Figure 7D-b)
and invasion (Figure 7D-c), following phosphorylation and
expression of LYRIC (Figure 7D-a).
To further determine whether DNP-mediated LYRIC
phosphorylation at serine 568 is associated with NPC
metastasis in vivo, phospho-LYRIC expression was de-
tected in metastatic nodes in the nude mice lungs by
immunohistochemistry. Phospho-LYRIC expression was
higher in the metastatic tumors of DNP-treated mice
(Figure 8A-b) than in those of the untreated control
mice (Figure 8A-a). The COOH terminal of LYRIC
(amino acid 546–582) is the predominant regulator of
nuclear localization [40], and its phosphorylation may
regulate LYRIC nuclear localization. To confirm whether
DNP-mediated phospho-LYRIC regulates its nuclear
localization, the phospho-LYRIC ratios of the nucleus to
the cytoplasm were determined in metastatic tumor
cells. The results illustrated in Figure 8B indicate thatthe ratio (nucleus to cytoplasm) was higher in metastatic
tumors with DNP treatment than in NPC in situ from
the untreated tumor. Together, our data indicate that
DNP mediates LYRIC expression and phosphorylation,
increases cell motility and invasion, and facilitates NPC
metastasis (Figure 8C).
Discussion
In clinical settings, NPC is considered as a highly inva-
sive and metastatic cancer. Clinical assays indicated that
NPC patients with metastasis have a higher level of DNP
in the serum than patients without metastasis [13].Our
previous work showed that DNP is known to mediate
ezrin phosphorylation and promote NPC metastasis
[13]. Therefore, we speculated that DNP also induces
the phosphorylation of other proteins when mediating
metastasis. In the present study, we first confirmed
DNP-mediated NPC metastasis, and subsequently used
phosphoprotein proteomics to comprehensively identify
DNP-regulated phosphoproteins and phosphosites. We
found that DNP increased the expression of phosphory-
lated LYRIC, ferritin, Rho, and GTPase protein, and
decreased the expression of phosphorylated ANKIB1 pro-
tein, dynein heavy chain 17, eukaryotic translation initi-
ation factor 4B, triosephosphate isomerase, torsin-1A
protein 1, membrane-associated progesterone receptor
component 2, nuclear casein kinase, cyclin-dependent kin-
ase substrate 1, and nucleolar RNA helicase, which are
associated with protein synthesis, cellular movement, mo-
lecular transport, cell death, and signaling pathways
related to cellular growth and proliferation.
Ferritins are important regulators of intracellular iron
content. They are made of 24 subunits assembled to
form the apoferritin shell. The protein subunits are of
two types, light chain and heavy chain, which share ex-
tensive homology. Increased ferritin concentration in tu-
mors has been recently reported in several malignancies,
such as colon and breast cancers [41-43], and seminoma.
Patients with NPC have higher levels of ferritin in the
serum [44], and ferritin has been reported to be associ-
ated with NPC development [45]. Furthermore, high
ferritin expression can enhance celluler growth and im-
prove resistance to oxidative stress in metastatic cancer
cells by interfering with their cellular antioxidant system
[46]. Ferritins play important roles in chemokine recep-
tor (CXCR)-mediated cell migration by forming a com-
plex with CXCR4 [47]. Phospho-ferritin at serine 178
increases binding to CXCR4 and nuclear translocation.
We speculate that DNP might influence NPC metastasis
by regulating ferritin phosphorylation.
Initiation of transcription is a complex biological
process that critically determines gene expression. Enor-
mous efforts over the decades have revealed a set of
proteins essential for this initiation by each class of
Figure 7 DNP induces motility and invasion through LYRIC phosphorylation. The 6-10B cells were transfected using pcDNA3.1, pcDNA3.1-LYRIC
or pcDNA3.1-LYRICmutant, and then the stably transfected 6-10B-mock, 6-10B-LYRIC and 6-10B-LYRICmutant cell lines were obtained by selection for
G418 resistance. LYRIC and phospho-LYRIC expressions were detected in these cells with or without DNP treatment (A). β-actin was used as a loading
control. Motility (B) and invasion (C) of 6-10B-mock, 6-10B-LYRIC, and 6-10B-LYRICmutant cells were determined in these cells. D, CNE1 cells were treated
with DNP at 6 μM, and LYRIC and phospho-LYRIC expressions were detected using immunoblotting (a), and motility (b) and invasion (c) were measured
using Boyden chamber in these cell samples. Data are presented as means ± SD from 3 independent experiments. Results were analyzed using one-way
ANOVA with post-hoc Dunnett’s test (*, p < 0.05).
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and Dicer, are highly expressed in NPC tissue and pre-
dict NPC prognosis [48]. For RNA polymerase I (Pol I),
which is dedicated to transcription of the large rRNA
precursor, 2 transcription factors have been defined in
mammals. Phosphorylation at specific sites in Pol I is a
prerequisite for proper transcription initiation, and
phosphorylation/dephosphorylation of Pol I is one of the
mechanisms by which cellular rDNA transcriptionalactivity could be modulated [49]. In DNP-mediated NPC
metastasis, DNP might induce Pol I phosphorylation,
thereby regulating DNA translocation. Activating tran-
scription factor 7-interacting protein 1 (ATF7IP) is highly
expressed in human cancers of many different tissues, sug-
gesting that it has an important role in tumorigenesis.
ATF7IP is required for the Sp1-dependent maintenance of
telomerase activity in cancer cells. Hepatocyte growth
factor/scatter factor (HGF/SF) is a pleiotropic cytokine/
Figure 8 Phospho-LYRIC and LYRIC expression in the metastatic tumors induced by DNP. The metastatic tumor samples were embedded.
Tissue sections of 4-μm thickness were prepared, and deparaffinized in xylene, and rehydrated in a graded alcohol series. Phospho-LYRIC and
LYRIC were detected in these sections using immunohistochemistry. A, Paraffin sections were stained with hematoxylin and eosin as well as
with antibodies against or LYRCI or phospho-LYRIC S568. a, c and e, The untreated 6-10B cells (NPC in situ) used as control; b, d and f, The
DNP-treated 6-10B cells. Arrow, positive cell. Magnification, × 400. Scale bar, 5 μm. H & E, hematoxylin and eosin. B, Phospho-LYRIC was quantified
in the nucleus and cytoplasm of metastatic tumor cells by using ImageMaster software, and phospho-LYRIC rates of nucleus to cytoplasm were
calculated. C, Schematic illustration of DNP-induced metastasis. DNP-mediated LYRIC phosphorylation increases the motility and invasion, leading
to metastasis of NPC cells.
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http://www.biomedcentral.com/1471-2407/14/243growth factor that is capable of inducing a remarkable var-
iety of biological activities, including cellular proliferation,
scattering, tubulogenesis, and invasiveness. HGF/SF can
induce cyclin D1 expression in mouse melanoma cells,
and this up-regulation is mediated in part by activating
transcription factor-2 [50]. Rho family GTPases, including
RhoA, B, C, Rac1, 2, and Cdc42, control cellular morph-
ology and motility [51]. Many of these effects are attrib-
uted directly or indirectly to their ability to regulate the
cytoskeleton. The most distinct effects of these GTPases
were noted in Swiss 3 T3 cells, in which RhoA induced
stress fiber formation and Rac1 induced membrane ruf-
fling and lamellipodia, whereas Cdc42 induced spike-like
filopodia [40]. In a previous study, Rho GTPase gene
(DLC1) is inactivated by DNA methylation, and was nega-
tively regulated in NPC carcinogenesis, whereas DLC-1
expression was detected in NPC cells after 5-aza-dC treat-
ment [52]. In our previous work, we found that DNP acti-
vates Rho kinase and PKC, induces ezrin phosphorylation
at threonine 567, increases fiber growth, and promotes
motility and invasion of cells [13]. In the present study,
phospho-ezrin was not detected, probably because of the
incompatibility of TiO2 phosphopeptide enrichment orSILAC for ezrin phosphorylation at threonine. Neverthe-
less, DNP mediated the expression of Rho family GTPase
and induced cancer metastasis. We believe that DNP also
mediates NPC metastasis by increasing the expression of
Rho family GTPases. LYRIC protein, also known as metas-
tasis adhesion protein, is involved in cancer metastasis
[44]. Using the evidence from two independent experi-
ments, we suggest that DNP mediates NPC metastasis by
inducing LYRIC phosphorylation at serine 568. First, DNP
enhanced cell motility and invasion following higher
expression of phospho-LYRIC. When the LYRIC phos-
phorylation site serine 568 was mutated, DNP-mediated
motility and invasion was dramatically decreased. Sec-
ondly, higher levels of phospho-LYRIC were detected
in DNP-induced metastatic tumors. Additionally, higher
phospho-LYRIC expression at serine 568 was also de-
tected in the NPC tissues, and it was expressed at higher
levels in the metastatic tissues than in primary site tissues
(Additional file 3: Figure S1). The COOH terminal of
LYRIC (amino acid 546–582) is the predominant regulator
of nuclear localization, and its modification by ubiquitin
regulates LYRIC nuclear localization [40]. We speculate
that DNP mediates the phosphorylation of LYRIC at
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thereby enhancing its function and facilitate NPC metasta-
sis. However, the function of phospho-LYRIC is not still
clearly understood. Further studies are required to clarify
whether LYRIC phosphorylation regulates LYRIC nuclear
localization, and which kinase mediates LYRIC phosphor-
ylation, in order to elucidate the mechanism that drives
the enhanced metastasis of NPC.
Conclusion
DNP regulates multiple signaling pathways through pro-
tein phosphorylation, including LYRIC at serine 568, and
mediates NPC metastasis. These findings provide insights
on the complexity and dynamics of DNP-involved metas-
tasis, and may facilitate a better understanding of the
mechanisms that favor the enhanced metastasis of NPC.
Additional files
Additional file 1: Table S1. DNP-regulated phosphopeptides identified
using a SILAC quantitative proteomics approach.
Additional file 2: Table S2. Different phosphopeptides mediated by DNP.
Additional file 3: Figure S1. Phospho-LYRIC expression in the primary
and metastatic tumor tissue of NPC patient. 31 primary NPC tissues were
from the nasopharyngeal biopsy tissues of NPC patients, and 27
metastatic tumor tissues were from the cervical lymph metastatic node.
The primary NPC and metastatic tumor samples were embedded, and 4
μm-thick tissue sections were deparaffinized in xylene, rehydrated in a
graded alcohol series. Phospho-LYRIC was detected in these sections
using immunohistochemistry. a, Primary NPC paraffin sections were
stained with antibody against phospho-LYRIC S568; b, Metastatic tumor
tissues were stained with antibody against phospho-LYRIC S568; c,
Primary NPC tissues were stained with hematoxylin and eosin; d,
Metastatic tumor tissues were stained with hematoxylin and eosin.
Arrow, positive cells. Original magnification, × 400. Scale bar, 5μm.
H & E, hematoxylin and eosin.
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